118 245

Cited 6 times in

Increased Sclerostin Level after Further Ablation of Remnant Estrogen by Aromatase Inhibitors

Authors
 Wonjin Kim  ;  Yoonjung Chung  ;  Se Hwa Kim  ;  Sehee Park  ;  Jae Hyun Bae  ;  Gyuri Kim  ;  Su Jin Lee  ;  Jo Eun Kim  ;  Byeong Woo Park  ;  Sung Kil Lim  ;  Yumie Rhee 
Citation
 Endocrinology and Metabolism (대한내분비학회지), Vol.30(1) : 58-64, 2015 
Journal Title
 Endocrinology and Metabolism (대한내분비학회지) 
ISSN
 2093-596X 
Issue Date
2015
Keywords
Aromatase inhibitors ; Breast neoplasms ; Osteoporosis ; Sclerostin
Abstract
BACKGROUND: Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which inhibits bone formation. Aromatase inhibitors (AIs), which reduce the conversion of steroids to estrogen, are used to treat endocrine-responsive breast cancer. As AIs lower estrogen levels, they increase bone turnover and lower bone mass. We analyzed changes in serum sclerostin levels in Korean women with breast cancer who were treated with an AI. METHODS: We included postmenopausal women with endocrine-responsive breast cancer (n=90; mean age, 57.7 years) treated with an AI, and compared them to healthy premenopausal women (n=36; mean age, 28.0 years). The subjects were randomly assigned to take either 5 mg alendronate with 0.5 μg calcitriol (n=46), or placebo (n=44) for 6 months. RESULTS: Postmenopausal women with breast cancer had significantly higher sclerostin levels compared to those in premenopausal women (27.8±13.6 pmol/L vs. 23.1±4.8 pmol/L, P<0.05). Baseline sclerostin levels positively correlated with either lumbar spine or total hip bone mineral density only in postmenopausal women (r=0.218 and r=0.233; P<0.05, respectively). Serum sclerostin levels increased by 39.9%±10.2% 6 months after AI use in postmenopausal women; however, no difference was observed between the alendronate and placebo groups (39.9%±10.2% vs. 55.9%±9.13%, P>0.05). CONCLUSION: Serum sclerostin levels increased with absolute deficiency of residual estrogens in postmenopausal women with endocrine-responsive breast cancer who underwent AI therapy with concurrent bone loss.
Files in This Item:
T201501309.pdf Download
DOI
10.3803/EnM.2015.30.1.58
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Gyuri(김규리)
Kim, Won Jin(김원진)
Kim, Jo Eun(김조은)
Park, Byeong Woo(박병우) ORCID logo https://orcid.org/0000-0003-1353-2607
Park, Se Hee(박세희)
Bae, Jae Hyun(배재현) ORCID logo https://orcid.org/0000-0002-3462-890X
Lee, Su Jin(이수진) ORCID logo https://orcid.org/0000-0002-7325-2538
Rhee, Yumie(이유미) ORCID logo https://orcid.org/0000-0003-4227-5638
Lim, Sung Kil(임승길)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/140008
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse